Table 2 Characteristics of the included studies
From: Periodontitis is associated with the increased levels of visfatin: a meta-analysis
Author | Year | Country | Study design | Group and size | Age | BMI | Systematic conditions | Periodontal treatment | Time interval | Sample |
|---|---|---|---|---|---|---|---|---|---|---|
Abolfazli, N [16] | 2015 | Iran | Single-armed clinical trial | Periodontitis (18) | 41.16 ± 7.59 | 24.35 ± 0.63 | Healthy | SRP | 4 weeks | Serum and saliva |
Bahammam, M. A [17] | 2018 | Saudi Arabia | Case-controlled | Control(20)/Periodontitis and T2DM (20)/Periodontitis(20)/Periodontitis and T2DM using simvastatin(20) | 32–50 | NA | Healthy/T2dM/Healthy/T2dM | NA | NA | GCF |
Çetiner, D [18] | 2019 | Turkey | Case-controlled | Periodontitis (9)/Control(10)/Obese and periodontitis (21)/Obese control (10) | 44.67 ± 10.87/46.50 ± 12.0 ( Non-obese); 44.22 ± 6.7/27.80 ± 3.12(Obese) | BMI < 25 ( Non-obese); BMI ≥ 30(Obese) | Healthy/Healthy/Obese/Obese | NA | NA | GCF |
Chen, F. [19] | 2018 | China | Case-controlled | Periodontitis (79)/Control (25) | Male (Female): 30(27) /30(25) | NA | Healthy/Healthy | NA | NA | Serum |
Coutinho, A [20] | 2021 | India | Case-controlled | Periodontitis (20)/Control (20) | 20–50 | 18.5–29.9 | Healthy/Healthy | NA | NA | Saliva |
Hamdi, A. Q [21] | 2021 | Iraq | Case-controlled | Periodontitis and T2DM (41)/Control (49) | 60 ± 14/61.8 ± 12.5 | NA | T2DM/Healthy | NA | NA | Serum |
Mishra, V [22] | 2016 | India | Case-controlled; Clinical trial | Control(14)/Periodontitis (14)/Periodontitis and T2DM (14) | 32.43/41.7/48.07 | NA | Healthy/Healthy/T2DM | SRP | 4Â weeks | GCF |
Mohamed, H. G [23] | 2015 | USA | Case-controlled | T2DM and periodontitis (54)/T2DM control(24)/ Periodontitis (30) Control (44) | 54.76 ± 1.38/50.79 ± 2.09/55.37 ± 1.77/47.15 ± 1.56 | NA | Healthy/Healthy/T2DM/T2DM | NA | NA | GCF |
Mopidevi, A [24] | 2019 | India | Case-controlled; Single-armed clinical trial | Periodontitis (10)/Control (10) | 43.9 ± 9.65/44.1 ± 8.41 | 24.68 ± 2.65/24.37 ± 2.54 | Healthy/Healthy | SRP and Surgical periodontal therapy | 12 weeks | Saliva |
Özcan, E.(A) [25] | 2016 | Turkey | Case-controlled; Single-armed clinical trial | Periodontitis (17)/Control (15) | 41.52 ± 6.34 /44.06 ± 5.36 | 24.12 ± 0.78/ 23.62 ± 1.53 | Healthy/Healthy | SRP | 3 months and 6 months | Saliva |
Özcan, E.(B) [26] | 2016 | Turkey | Case-controlled | Periodontitis (27)/Control (18) | 41.59 ± 7.23/37.72 ± 9.02 | 24.74 ± 1.22/24 ± 1.04 | Healthy/Healthy | NA | NA | GCF |
Özcan, E [27] | 2015 | Turkey | Case-controlled | Periodontitis (25)/Control (23) | 32.56 ± 7.92/34.50 ± 7.09 | 23.50 (21.20–26.15)/24.55(21.92–28.17) | Healthy/Healthy | NA | NA | Saliva |
Paul, R [28] | 2020 | India | Case-controlled | Periodontitis (30)/Control (30) | 30–55 | NA | Healthy/Healthy | NA | NA | GCF |
Pradeep, A. R [29] | 2011 | India | Case-controlled | Periodontitis (15)/Control (10)/Gingivitis(15) | 32.6 ± 7.5 /28.70 ± 3.6/ 28.5 ± 3.1 | NA | Healthy/Healthy | NA | NA | Serum and GCF |
Pradeep, A. R [30] | 2012 | India | Case-controlled | Control(10/Periodontitis and T2DM(10)/Periodontitis (10) | 31.33 ± 3.478/38.80 ± 5.634/32.60 ± 7.59 | 27.28 ± 2.41 /28.46 ± 2.72 /28.59 ± 3.14 | Healthy/T2DM/Healthy | NA | NA | Serum and GCF |
Raghavendra, N. M [31] | 2012 | India | Case-controlled; Single-armed clinical trial | Periodontitis (15)/Control (15) | 38.80 ± 5.634/31.33 ± 3.478 | NA | Healthy/Healthy | SRP | 8 weeks | Serum and GCF |
Rezaei, M [32] | 2019 | Iran | Case-controlled | SLE and periodontitis (15)/SLE control(15)/ Periodontitis (15) Control (15) | 44.17 ± 3.21/44.89 ± 3.07/45.03 ± 3.14/44.99 ± 3.26 | 21.89 ± 1.83/22.02 ± 1.17/23.05 ± 1.65/22.65 ± 2.10 | SLE/SLE/Healthy/Healthy | NA | NA | GCF |
Saljoughi, F [33] | 2020 | Iran | Case-controlled | PCOS and periodontitis (30)/PCOS control(25)/ Periodontitis (23) Control (32) | 45.2 ± 3.2/45.3 ± 3.0/45.3 ± 3.1/45.5 ± 3.3 | 22.43 ± 1.79/22.13 ± 1.58/22.38 ± 1.71/22.07 ± 1.50 | PCOS/PCOS/Healthy/Healthy | NA | NA | GCF |
Saseendran, G [34] | 2021 | India | Case-controlled; Clinical trial | Control (16)/Gingivitis(16)/Periodontitis(16) | 25–50 | NA | Healthy/Healthy/Healthy | SRP | 2 months | Saliva |
Tabari, Z. A [35] | 2014 | Iran | Case-controlled | Periodontitis (20)/Control (20) | 38.45 ± 9.98/33.85 ± 6.84 | 23.66 ± 2.99/21.88 ± 2.56 | Healthy/Healthy | NA | NA | Saliva |
Tabari, Z. A [36] | 2015 | Iran | Case-controlled; Single-armed clinical trial | Periodontitis (20)/Control (20) | 38.45 ± 9.98/33.85 ± 6.84 | 23.66 ± 2.99/21.88 ± 2.56 | Healthy/Healthy | SRP | 1 months | Saliva |
Wu, Y [37] | 2015 | China | Randomized clinical trial | T2DM and periodontitis (23)/T2DM and periodontitis (23) | 54.09 ± 6.57/55.52 ± 5.22 | 22.22 ± 0.64/22.14 ± 0.72 | T2DM/T2DM | SRP | 3 months and 6 months | Serum and GCF |
Ziaei, N [38] | 2020 | Iran | Single-armed clinical trial | T2DM and periodontitis (20) | 51.85 ± 6.42 | 26.8 ± 1.5 | T2DM | SRP | 3 months | Saliva |